top of page

Latest results from SHIGETECVAX to be presented at the VASE conference 2022

  • EVI
  • Nov 29, 2022
  • 1 min read

Updated: Dec 6, 2022

29 November 2022


The Vaccines Against Shigella and ETEC (VASE) Conference is an international gathering dedicated to developing Shigella and enterotoxigenic Escherichia coli (ETEC) vaccines. Hosted by PATH, a global non-profit organisation dedicated to achieving health equity, it’s an event for people like you who care about improving public health and saving lives by reducing diarrheal disease.

The latest results from EVI-coordinated SHIGETECVAX project funded by the European Commission under the Horizon 2020 Framework Programme will be presented at the VASE conference 2022 to be held in Washington on 29 November–01 December 2022. Dr Aicha Sayeh is representing EVI.


The safety and immunogenicity data of a combined Shigella/ETEC live attenuated vaccine candidate that was tested in a phase Ia clinical trial in Hungary will be presented by Eveliqure Biotechnologies Gmbh. Based on these encouraging results, a phase Ib trial in the endemic population in Bangladesh is being prepared by the project partners.


 
 
 

Comments


Join European Vaccine Initiative mailing list for updates on projects, training and funding opportunities

Thanks for subscribing! If you have any questions or would like to unsubscribe contact us at communication@euvaccine.eu.

  • LinkedIn - White Circle
  • Twitter - White Circle
EU emblem_flag_yellow_high (1).jpg

This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 815568

© 2024 European Vaccine Initiative. Designed by European Vaccine Initiative

bottom of page